Initial High-Efficacy MS Therapy Tied to Less Disability Later

Damian McNamara

May 05, 2020

Starting treatment for relapsing-remitting multiple sclerosis (MS) with high-efficacy therapy (HET) is associated with lower long-term disability compared with a step-wise increase to reach more aggressive treatment later, new research suggests.

However, there was a trade-off: In this study of nearly 300 patients, those treated with initial HET experienced more disease activity in the first 2 years than other participants.

The HET benefit emerged between 2 and 10 years into the study. For example, the mean Expanded Disability Status Scale (EDSS) scores were significantly lower at 6 years in the early, aggressive treatment group than in the later HET group (2.4 vs 3.3, respectively).

"Treatment decisions made around the time of diagnosis will affect long-term outcomes," lead author Anna He, MBBS, Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden and the UCL Queen Square Institute of Neurology in London, United Kingdom, told Medscape Medical News.

Using the most efficacious disease-modifying therapies from the start minimizes disability, "whereas those patients escalating to high-efficacy disease-modifying therapies later don't seem to catch up to those who commenced earlier," He said.

"Patients and clinicians should be aware of this when choosing treatment in early MS," she added.

This research is being presented on AAN.com as part of the 2020 American Academy of Neurology Science Highlights.

Patient-Centered Outcome

Instead of measures of brain volume, lesion count, serum neurofilament, or other biomarkers that are mainly of interest to clinicians and scientists, "the main outcome of interest to our patients is their disability," He said. "The first question they ask at diagnosis is usually along the lines of, 'What will my disability be in 10 years?' "

"This is what matters to patients and is fundamentally what motivated this study," He added.

The investigators searched international MS registries for patients with relapsing-remitting MS starting HET, which included rituximab, ocrelizumab, mitoxantrone, alemtuzumab, or natalizumab.

They compared 117 participants who started HET within the first 2 years of clinical disease onset (the early group) with 181 participants who started HET after more than 4 years (the late group). All were followed for a median of 7.4 years (range, 6.4 to 8.6 years). 

Difference in EDSS scores from baseline was the primary outcome. Both cohorts began the study with a mean EDSS score of 2.4, but between-group differences were significant at 10 years.

The secondary outcome of cumulative hazard of disability progression was higher in the early-treatment group from baseline to 2 years. Between the period of 2 and 10 years, the inverse was true.

In patients with highly active MS, "early exposure to high efficacy therapies is recommended," He noted.

"We can already affect our patients' lives enormously by utilizing our current toolbox in the most optimal way. It is our task to optimize this in a data-driven manner."

Going forward, He plans to look at other outcomes, including patient-reported quality of life and health economic measures, and to take a different approach to future research.

Rather than assess MS outcomes from a disease-biology perspective, "I will be looking at MS outcomes from the perspective of its key stakeholders — the individual and society," and the factors that influence them, He said.

Confirmatory Evidence?

Commenting on the findings for Medscape Medical News, Robert Gross, MD, a neurologist at the Rocky Mountain MS Center at the University of Colorado Denver in Aurora, said it's "hard to believe we are still having this debate" about earlier vs later HET.

There are now "numerous studies, including head-to-head trials and large cohort studies, showing superiority of highly efficacious agents to older disease-modifying therapies of more limited efficacy, as well as better outcomes with early vs delayed use of high-efficacy therapy," said Gross, who was not involved with the current research.

"This study further adds to the evidence that we should be preferentially starting folks with relapsing-remitting MS right away on high-efficacy therapy, rather than waiting for relapses and disease progression to occur," he added.  

American Academy of Neurology (AAN) 2020 Annual Meeting: Abstract S29.006

He and Gross have disclosed no relevant financial relationships.

Follow Damian McNamara on Twitter: @MedReporter. For more Medscape Neurology news, join us on Facebook and Twitter .

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....